{
    "nct_id": "NCT05756166",
    "official_title": "Phase I/IIa Clinical Trial Evaluating the Safety and Efficacy of Rintatolimod Combined With IFNα2b (Bioferon®) to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer",
    "inclusion_criteria": "* Age >= 18 years of age\n* Have pathologically confirmed diagnosis of PDL-1-negative or PDL1 positive unresectable or metastatic TNBC with no curative treatment options\n* Have been informed of other treatment options\n* Patient has lesion that can be biopsied and is willing to undergo the procedure as part of the protocol. Note: For cohort 1 and cohort 2: Patient with accessible tumor will be offered optional pre-treatment and post-treatment biopsies. Biopsies are mandatory for cohort 3\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 1\n* Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n* Ability to swallow and retain oral medication\n* Have measurable disease per RECIST 1.1 criteria present\n* Any line of therapy allowed, radiologically confirmed progression\n* No cancer-directed therapy for at least 3 weeks prior to study treatment (bone-directed therapies are allowed)\n* Platelets >= 100,000/uL\n* Hemoglobin >= 9.0 g/dL\n* Absolute neutrophil count (ANC) >= 1500/uL\n* Total bilirubin =< institutional upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X institutional ULN\n* Creatinine < ULN or, creatinine clearance >= 50 mL/min per Cockcroft-Gault equation for patients with creatinine levels greater than ULN\n* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients currently treated with systemic immunosuppressive agents, including steroids (greater than equivalent of 10 mg daily of prednisone), are ineligible until 3 weeks after removal from immunosuppressive treatment. (Inhaled steroids are allowed.)\n* Patients with active autoimmune disease or history of transplantation\n* Pregnant or nursing female participants\n* Unwilling or unable to follow protocol requirements\n* Patients with known serious mood disorders. (Major depression diagnosis is an exclusion. Other stable mood disorders on stable therapy for > 6 months or not requiring therapy may be allowed after consultation with the principal investigator.)\n* Cardiac risk factors including:\n\n  * Patients experiencing cardiac event(s) (acute coronary syndrome, myocardial infarction, or ischemia) within 3 months of signing consent. While our published clinical studies involving short-term CKM did not indicate increased risk of cardiac events, the CKM can induce flu-like symptoms, providing justification for its avoidance in patients with recent cardiac events\n  * Patients with a New York Heart Association classification of III or IV\n  * Patients with a history of stroke\n* History of upper gastrointestinal ulceration, upper gastrointestinal bleeding, or upper gastrointestinal perforation within the past 3 years\n* Prior allergic reaction or hypersensitivity to nonsteroidal antiinflammatory drug (NSAIDs) or any drugs administered on protocol\n* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug\n* Any patients with a positive antinuclear antibodies test will be excluded from study\n* Has a known history of human immunodeficiency virus (HIV) infection\n* Concurrent active hepatitis B (defined as hepatitis B antigen [HBsAg] positive and/or detectable hepatitis B virus [HBV] deoxyribonucleic acid [DNA]) and hepatitis C virus (defined as anti-hepatitis C virus [HCV] antibody [Ab] positive and detectable HCV ribonucleic acid [RNA]) infection. Note: Hepatitis B and C screening tests are not required unless known history of HBV and HCV infection",
    "miscellaneous_criteria": ""
}